A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41

Journal of Virology

Volumn 84, Issue 14, 2010, Pages 7288-7299

  Murray, Edward J ^a   Leaman, Daniel P ^b   Pawa, Nishant ^c   Perkins, Hannah ^a   Pickford, Chris ^a   Perros, Manos ^a,d   Zwick, Michael B ^b   Butler, Scott L ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d NOVARTIS INSTITUTE FOR TROPICAL DISEASES   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; DISULFIDE; ENVELOPE PROTEIN; FURIN; GLYCOPROTEIN GP 41; PD 4087738; PD 549084; PF 348089; PF 4087738; PF 549084; PF 68742; PLERIXAFOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG TARGETING; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN TARGETING; VIRION; VIRUS STRAIN;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; MOLECULAR WEIGHT; MUTATION; PYRIDONES; RECEPTORS, CCR5; RECEPTORS, CXCR4; SEQUENCE ALIGNMENT; SULFONAMIDES; VIRUS INTERNALIZATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77953771721     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00535-10     Document Type: Article

References (66)

1. Anastassopoulou, C. G., T. J. Ketas, P. J. Klasse, and J. P. Moore. 2009. Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. Proc. Natl. Acad. Sci. U. S. A. 106:5318-5323.
2. Baldwin, C. E., R. W. Sanders, Y. Deng, S. Jurriaans, J. M. Lange, M. Lu, and B. Berkhout. 2004. Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. J. Virol. 78:12428-12437.
3. Bar, S., and M. Alizon. 2004. Role of the ectodomain of the gp41 transmembrane envelope protein of human immunodeficiency virus type 1 in late steps of the membrane fusion process. J. Virol. 78:811-820.
4. Bianchi, E., M. Finotto, P. Ingallinella, R. Hrin, A. V. Carella, X. S. Hou, W. A. Schleif, M. D. Miller, R. Geleziunas, and A. Pessi. 2005. Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection. Proc. Natl. Acad. Sci. U. S. A. 102:12903-12908.
5. Binley, J. M., R. W. Sanders, B. Clas, N. Schuelke, A. Master, Y. Guo, F. Kajumo, D. J. Anselma, P. J. Maddon, W. C. Olson, and J. P. Moore. 2000. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J. Virol. 74:627-643. (Pubitemid 30036198)
6. Bjorndal, A., H. Deng, M. Jansson, J. R. Fiore, C. Colognesi, A. Karlsson, J. Albert, G. Scarlatti, D. R. Littman, and E. M. Fenyo. 1997. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J. Virol. 71:7478-7487. (Pubitemid 27391688)
7. Bradley, J., J. Gill, F. Bertelli, S. Letafat, R. Corbau, P. Hayter, P. Harrison, A. Tee, W. Keighley, M. Perros, G. Ciaramella, A. Sewing, and C. Williams. 2004. Development and automation of a 384-well cell fusion assay to identify inhibitors of CCR5/CD4-mediated HIV virus entry. J. Biomol. Screen. 9:516-524.
8. Burton, D. R., J. Pyati, R. Koduri, S. J. Sharp, G. B. Thornton, P. W. Parren, L. S. Sawyer, R. M. Hendry, N. Dunlop, P. L. Nara, et al. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024-1027.
9. Cai, L., and M. Gochin. 2007. A novel fluorescence intensity screening assay identifies new low-molecular-weight inhibitors of the gp41 coiled-coil domain of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 51:2388-2395.
10. Cavacini, L., M. Duval, L. Song, R. Sangster, S. H. Xiang, J. Sodroski, and M. Posner. 2003. Conformational changes in env oligomer induced by an antibody dependent on the V3 loop base. AIDS 17:685-689. (Pubitemid 36521074)
11. Connor, R. I., B. K. Chen, S. Choe, and N. R. Landau. 1995. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206:935-944.
12. Debnath, A. K. 6 June 2006. Antiviral composites comprising heterocyclic substituted phenyl furans and related compounds. Patent application WO/2006/138118 A2.
13. De Clercq, E. 2003. The bicyclam AMD3100 story. Nat. Rev. Drug Discov. 2:581-587.
14. Dimitrov, A. 2007. Ibalizumab, a CD4-specific MAb to inhibit HIV-1 infection. Curr. Opin. Invest. Drugs 8:653-661.
15. Dimitrov, A. S., A. Jacobs, C. M. Finnegan, G. Stiegler, H. Katinger, and R. Blumenthal. 2007. Exposure of the membrane-proximal external region of HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion. Biochemistry 46:1398-1401.
16. Dimmock, N. J. 2005. The complex antigenicity of a small external region of the C-terminal tail of the HIV-1 gp41 envelope protein: a lesson in epitope analysis. Rev. Med. Virol. 15:365-381.
17. Doranz, B. J., S. S. Baik, and R. W. Doms. 1999. Use of a gp120 binding assay to dissect the requirements and kinetics of human immunodeficiency virus fusion events. J. Virol. 73:10346-10358.
18. Dorr, P., M. Westby, S. Dobbs, P. Griffin, B. Irvine, M. Macartney, J. Mori, G. Rickett, C. Smith-Burchnell, C. Napier, R. Webster, D. Armour, D. Price, B. Stammen, A. Wood, and M. Perros. 2005. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49:4721-4732.
19. Eckert, D. M., and P. S. Kim. 2001. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc. Natl. Acad. Sci. U. S. A. 98:11187-11192.
20. Eckert, D. M., and P. S. Kim. 2001. Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70:777-810.
21. Eckert, D. M., V. N. Malashkevich, L. H. Hong, P. A. Carr, and P. S. Kim. 1999. Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 99:103-115.
22. Este, J. A., and A. Telenti. 2007. HIV entry inhibitors. Lancet 370:81-88.
23. Finnegan, C. M., I. Burinski, T. Jackson, A. Castillo, N. Kilgore, M. Reddick, A. Yunus, M. Zuiderhoff, T. Nitz, C. Wild, G. Allaway, and K. Salzwedel. 2006. Validation of a novel approach for HIV-1 fusion inhibitor drug discovery. XVI International AIDS Conference, Toronto, Ontario, Canada.
24. Frey, G., S. Rits-Volloch, X. Q. Zhang, R. T. Schooley, B. Chen, and S. C. Harrison. 2006. Small molecules that bind the inner core of gp41 and inhibit HIV envelope-mediated fusion. Proc. Natl. Acad. Sci. U. S. A. 103:13938-13943.
25. Guilhaudis, L., A. Jacobs, and M. Caffrey. 2002. Solution structure of the HIV gp120 C5 domain. Eur. J. Biochem. 269:4860-4867.
26. Harrison, S. C. 2008. Viral membrane fusion. Nat. Struct. Mol. Biol. 15:690-698.
27. Helseth, E., U. Olshevsky, C. Furman, and J. Sodroski. 1991. Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein. J. Virol. 65:2119-2123.
28. Ho, H. T., L. Fan, B. Nowicka-Sans, B. McAuliffe, C. B. Li, G. Yamanaka, N. Zhou, H. Fang, I. Dicker, R. Dalterio, Y. F. Gong, T. Wang, Z. Yin, Y. Ueda, J. Matiskella, J. Kadow, P. Clapham, J. Robinson, R. Colonno, and P. F. Lin. 2006. Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events. J. Virol. 80:4017-4025.
29. Holz-Smith, S. L., I. C. Sun, L. Jin, T. J. Matthews, K. H. Lee, and C. H. Chen. 2001. Role of human immunodeficiency virus (HIV) type 1 envelope in the anti-HIV activity of the betulinic acid derivative IC9564. Antimicrob. Agents Chemother. 45:60-66.
30. Huang, L., W. Lai, P. Ho, and C. H. Chen. 2007. Induction of a nonproductive conformational change in gp120 by a small molecule HIV type 1 entry inhibitor. AIDS Res. Hum. Retrovir. 23:28-32.
31. Jacobs, A., J. Sen, L. Rong, and M. Caffrey. 2005. Alanine scanning mutants of the HIV gp41 loop. J. Biol. Chem. 280:27284-27288.
32. Jiang, S., K. Lin, N. Strick, and A. R. Neurath. 1993. HIV-1 inhibition by a peptide. Nature 365:113.
33. Jiang, S., H. Lu, S. Liu, Q. Zhao, Y. He, and A. K. Debnath. 2004. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrob. Agents Chemother. 48:4349-4359.
34. Kadkhodayan, S., L. O. Elliott, G. Mausisa, H. A. Wallweber, K. Deshayes, B. Feng, and W. J. Fairbrother. 2007. Evaluation of assay technologies for the identification of protein-peptide interaction antagonists. Assay Drug Dev. Technol. 5:501-513.
35. Kilgore, N. R., K. Salzwedel, M. Reddick, G. P. Allaway, and C. T. Wild. 2003. Direct evidence that C-peptide inhibitors of human immunodeficiency virus type 1 entry bind to the gp41 N-helical domain in receptor-activated viral envelope. J. Virol. 77:7669-7672.
36. Kim, S., H. B. Pang, and M. S. Kay. 2008. Peptide mimic of the HIV envelope gp120-gp41 interface. J. Mol. Biol. 376:786-797.
37. Koshiba, T., and D. C. Chan. 2003. The prefusogenic intermediate of HIV-1 gp41 contains exposed C-peptide regions. J. Biol. Chem. 278:7573-7579.
38. Labrosse, B., O. Pleskoff, N. Sol, C. Jones, Y. Henin, and M. Alizon. 1997. Resistance to a drug blocking human immunodeficiency virus type 1 entry (RPR103611) is conferred by mutations in gp41. J. Virol. 71:8230-8236. (Pubitemid 27446398)
39. Labrosse, B., C. Treboute, and M. Alizon. 2000. Sensitivity to a nonpeptidic compound (RPR103611) blocking human immunodeficiency virus type 1 Env-mediated fusion depends on sequence and accessibility of the gp41 loop region. J. Virol. 74:2142-2150. (Pubitemid 30091467)
40. Lai, W., L. Huang, P. Ho, Z. Li, D. Montefiori, and C. H. Chen. 2008. Betulinic acid derivatives that target gp120 and inhibit multiple genetic subtypes of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 52:128-136.
41. Lalezari, J. P., K. Henry, M. O'Hearn, J. S. Montaner, P. J. Piliero, B. Trottier, S. Walmsley, C. Cohen, D. R. Kuritzkes, J. J. Eron, Jr., J. Chung, R. DeMasi, L. Donatacci, C. Drobnes, J. Delehanty, and M. Salgo. 2003. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. 348:2175-2185.
42. Leaman, D. P., H. Kinkead, and M. B. Zwick. 2010. In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1. J. Virol. 84:3382-3395.
43. Lee-Huang, S., P. L. Huang, D. Zhang, J. W. Lee, J. Bao, Y. Sun, Y. T. Chang, and J. Zhang. 2007. Discovery of small-molecule HIV-1 fusion and integrase inhibitors oleuropein and hydroxytyrosol. II. Integrase inhibition. Biochem. Biophys. Res. Commun. 354:879-884.
44. Liu, S., S. Wu, and S. Jiang. 2007. HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds. Curr. Pharm. Des. 13:143-162.
45. Louis, J. M., I. Nesheiwat, L. Chang, G. M. Clore, and C. A. Bewley. 2003. Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion. J. Biol. Chem. 278:20278-20285.
46. Maerz, A. L., H. E. Drummer, K. A. Wilson, and P. Poumbourios. 2001. Functional analysis of the disulfide-bonded loop/chain reversal region of human immunodeficiency virus type 1 gp41 reveals a critical role in gp120-gp41 association. J. Virol. 75:6635-6644.
47. Mariani, R., G. Rutter, M. E. Harris, T. J. Hope, H. G. Krausslich, and N. R. Landau. 2000. A block to human immunodeficiency virus type 1 assembly in murine cells. J. Virol. 74:3859-3870. (Pubitemid 30180328)
48. Martinez-Cajas, J. L., and M. A. Wainberg. 2008. Antiretroviral therapy: optimal sequencing of therapy to avoid resistance. Drugs 68:43-72.
49. Mayaux, J. F., A. Bousseau, R. Pauwels, T. Huet, Y. Henin, N. Dereu, M. Evers, F. Soler, C. Poujade, E. De Clercq, et al. 1994. Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells. Proc. Natl. Acad. Sci. U. S. A. 91:3564-3568.
50. Niwa, H., K. Yamamura, and J. Miyazaki. 1991. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108:193-199.
51. Pancera, M., S. Majeed, Y. E. Ban, L. Chen, C. C. Huang, L. Kong, Y. D. Kwon, J. Stuckey, T. Zhou, J. E. Robinson, W. R. Schief, J. Sodroski, R. Wyatt, and P. D. Kwong. Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc. Natl. Acad. Sci. U. S. A. 107:1166-1171.
52. Pascual, R., M. Contreras, A. Fedorov, M. Prieto, and J. Villalain. 2005. Interaction of a peptide derived from the N-heptad repeat region of gp41 Env ectodomain with model membranes: modulation of phospholipid phase behavior. Biochemistry 44:14275-14288. (Pubitemid 41533052)
53. Reed, S. E., E. M. Staley, J. P. Mayginnes, D. J. Pintel, and G. E. Tullis. 2006. Transfection of mammalian cells using linear polyethylenimine is a simple and effective means of producing recombinant adeno-associated virus vectors. J. Virol. Methods 138:85-98.
54. Reeves, J. D., S. A. Gallo, N. Ahmad, J. L. Miamidian, P. E. Harvey, M. Sharron, S. Pohlmann, J. N. Sfakianos, C. A. Derdeyn, R. Blumenthal, E. Hunter, and R. W. Doms. 2002. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc. Natl. Acad. Sci. U. S. A. 99:16249-16254.
55. Root, M. J., M. S. Kay, and P. S. Kim. 2001. Protein design of an HIV-1 entry inhibitor. Science 291:884-888. (Pubitemid 32120761)
56. Rusconi, S., A. Scozzafava, A. Mastrolorenzo, and C. T. Supuran. 2007. An update in the development of HIV entry inhibitors. Curr. Top. Med. Chem. 7:1273-1289.
57. Sen, J., A. Jacobs, H. Jiang, L. Rong, and M. Caffrey. 2007. The disulfide loop of gp41 is critical to the furin recognition site of HIV gp160. Protein Sci. 16:1236-1241. (Pubitemid 46849232)
58. Si, Z., N. Madani, J. M. Cox, J. J. Chruma, J. C. Klein, A. Schon, N. Phan, L. Wang, A. C. Biorn, S. Cocklin, I. Chaiken, E. Freire, A. B. Smith III, and J. G. Sodroski. 2004. Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc. Natl. Acad. Sci. U. S. A. 101:5036-5041.
59. Summa, V., A. Petrocchi, F. Bonelli, B. Crescenzi, M. Donghi, M. Ferrara, F. Fiore, C. Gardelli, O. Gonzalez Paz, D. J. Hazuda, P. Jones, O. Kinzel, R. Laufer, E. Monteagudo, E. Muraglia, E. Nizi, F. Orvieto, P. Pace, G. Pescatore, R. Scarpelli, K. Stillmock, M. V. Witmer, and M. Rowley. 2008. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J. Med. Chem. 51:5843-5855.
60. Trkola, A., M. Purtscher, T. Muster, C. Ballaun, A. Buchacher, N. Sullivan, K. Srinivasan, J. Sodroski, J. P. Moore, and H. Katinger. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70:1100-1108. (Pubitemid 26029030)
61. Ullman, E. F., H. Kirakossian, S. Singh, Z. P. Wu, B. R. Irvin, J. S. Pease, A. C. Switchenko, J. D. Irvine, A. Dafforn, C. N. Skold, et al. 1994. Luminescent oxygen channeling immunoassay: measurement of particle binding kinetics by chemiluminescence. Proc. Natl. Acad. Sci. U. S. A. 91:5426-5430.
62. UNAIDS. 2008, posting date. Report on the global AIDS epidemic: executive summary. UNAIDS, New York, NY. [Online.] http://data.unaids.org/pub/ GlobalReport/2008/jc1511-gr08-executivesummary-en.pdf.
63. Van Acker, K. L. A., et al. 22 March 2007. Entry inhibitors of the HIV virus. U.S. patent 20070066623 A1.
64. Wei, X., J. M. Decker, H. Liu, Z. Zhang, R. B. Arani, J. M. Kilby, M. S. Saag, X. Wu, G. M. Shaw, and J. C. Kappes. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905.
65. Zwick, M. B., A. F. Labrijn, M. Wang, C. Spenlehauer, E. O. Saphire, J. M. Binley, J. P. Moore, G. Stiegler, H. Katinger, D. R. Burton, and P. W. Parren. 2001. Broadly neutralizing antibodies targeted to the membraneproximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75:10892-10905. (Pubitemid 33034579)
66. Zwick, M. B., E. O. Saphire, and D. R. Burton. 2004. gp41: HIV's shy protein. Nat. Med. 10:133-134.